Literature DB >> 26506455

The mass action equation in pharmacology.

Terry Kenakin1.   

Abstract

The mass action equation is the building block from which all models of drug-receptor interaction are built. In the simplest case, the equation predicts a sigmoidal relationship between the amount of drug-receptor complex and the logarithm of the concentration of drug. The form of this function is also the same as most dose-response relationships in pharmacology (such as enzyme inhibition and the protein binding of drugs) but the potency term in dose-response relationships very often differs in meaning from the similar term in the simple mass action relationship. This is because (i) most pharmacological systems are collections of mass action reactions in series and/or in parallel and (ii) the important assumptions in the mass action reaction are violated in complex pharmacological systems. In some systems, the affinity of the receptor R for some ligand A is modified by interaction of the receptor with the allosteric ligand B and concomitantly the affinity of the receptor for ligand B is modified to the same degree. When this occurs, the observed affinity of the ligand A for the receptor will depend on both the concentration of the co-binding allosteric ligand and its nature. The relationships between drug potency in pharmacological models and the equilibrium dissociation constants defined in single mass action reactions are discussed. More detailed knowledge of efficacy has led to new models of drug action that depend on the relative probabilities of different states, and these have taken knowledge of drug-receptor interactions beyond Guldberg and Waage.
© 2015 The British Pharmacological Society.

Keywords:  dose-response; mass action; pharmacology; receptor

Mesh:

Substances:

Year:  2015        PMID: 26506455      PMCID: PMC4693573          DOI: 10.1111/bcp.12810

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  31 in total

Review 1.  The ligand paradox between affinity and efficacy: can you be there and not make a difference?

Authors:  Terry Kenakin; Ongun Onaran
Journal:  Trends Pharmacol Sci       Date:  2002-06       Impact factor: 14.819

2.  Ligands and signaling proteins govern the conformational landscape explored by a G protein-coupled receptor.

Authors:  Sophie Mary; Marjorie Damian; Maxime Louet; Nicolas Floquet; Jean-Alain Fehrentz; Jacky Marie; Jean Martinez; Jean-Louis Banères
Journal:  Proc Natl Acad Sci U S A       Date:  2012-05-09       Impact factor: 11.205

3.  TRV120027, a novel β-arrestin biased ligand at the angiotensin II type I receptor, unloads the heart and maintains renal function when added to furosemide in experimental heart failure.

Authors:  Guido Boerrigter; David G Soergel; Jonathan D Violin; Michael W Lark; John C Burnett
Journal:  Circ Heart Fail       Date:  2012-08-13       Impact factor: 8.790

Review 4.  Drug efficacy at G protein-coupled receptors.

Authors:  Terry Kenakin
Journal:  Annu Rev Pharmacol Toxicol       Date:  2002       Impact factor: 13.820

5.  The structural distribution of cooperative interactions in proteins: analysis of the native state ensemble.

Authors:  V J Hilser; D Dowdy; T G Oas; E Freire
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-18       Impact factor: 11.205

Review 6.  Multiple mechanisms of serotonergic signal transduction.

Authors:  B L Roth; D M Chuang
Journal:  Life Sci       Date:  1987-08-31       Impact factor: 5.037

Review 7.  Conformational substates in proteins.

Authors:  H Frauenfelder; F Parak; R D Young
Journal:  Annu Rev Biophys Biophys Chem       Date:  1988

Review 8.  Agonist-receptor efficacy. II. Agonist trafficking of receptor signals.

Authors:  T Kenakin
Journal:  Trends Pharmacol Sci       Date:  1995-07       Impact factor: 14.819

9.  Collateral efficacy as a pharmacological problem applied to new drug discovery.

Authors:  Terry Kenakin
Journal:  Expert Opin Drug Discov       Date:  2006-12       Impact factor: 6.098

10.  Atypical molecular pharmacology of a new long-acting beta 2-adrenoceptor agonist, TA 2005.

Authors:  H P Voss; D Donnell; A Bast
Journal:  Eur J Pharmacol       Date:  1992-12-01       Impact factor: 4.432

View more
  11 in total

Review 1.  Cato Guldberg and Peter Waage, the history of the Law of Mass Action, and its relevance to clinical pharmacology.

Authors:  Robin E Ferner; Jeffrey K Aronson
Journal:  Br J Clin Pharmacol       Date:  2015-10-22       Impact factor: 4.335

2.  Cell-Binding Assays for Determining the Affinity of Protein-Protein Interactions: Technologies and Considerations.

Authors:  S A Hunter; J R Cochran
Journal:  Methods Enzymol       Date:  2016-08-08       Impact factor: 1.600

3.  Differential Pharmacology and Binding of mGlu2 Receptor Allosteric Modulators.

Authors:  Daniel E O'Brien; Douglas M Shaw; Hyekyung P Cho; Alan J Cross; Steven S Wesolowski; Andrew S Felts; Jonas Bergare; Charles S Elmore; Craig W Lindsley; Colleen M Niswender; P Jeffrey Conn
Journal:  Mol Pharmacol       Date:  2018-03-15       Impact factor: 4.436

Review 4.  100 years of modelling ligand-receptor binding and response: A focus on GPCRs.

Authors:  David B Finlay; Stephen B Duffull; Michelle Glass
Journal:  Br J Pharmacol       Date:  2020-02-28       Impact factor: 8.739

5.  Employing the Operational Model to Measure System-Independent OTR Efficacy.

Authors:  Kiyan Afzali; Mark Connor
Journal:  Methods Mol Biol       Date:  2022

6.  Evaluating a transfer gradient assumption in a fomite-mediated microbial transmission model using an experimental and Bayesian approach.

Authors:  Amanda M Wilson; Marco-Felipe King; Martín López-García; Mark H Weir; Jonathan D Sexton; Robert A Canales; Georgiana E Kostov; Timothy R Julian; Catherine J Noakes; Kelly A Reynolds
Journal:  J R Soc Interface       Date:  2020-06-24       Impact factor: 4.118

7.  Does In Vitro Potency Predict Clinically Efficacious Concentrations?

Authors:  Rasmus Jansson-Löfmark; Stephan Hjorth; Johan Gabrielsson
Journal:  Clin Pharmacol Ther       Date:  2020-05-10       Impact factor: 6.875

8.  The Influence of Peptide Context on Signaling and Trafficking of Glucagon-like Peptide-1 Receptor Biased Agonists.

Authors:  Zijian Fang; Shiqian Chen; Philip Pickford; Johannes Broichhagen; David J Hodson; Ivan R Corrêa; Sunil Kumar; Frederik Görlitz; Chris Dunsby; Paul M W French; Guy A Rutter; Tricia Tan; Stephen R Bloom; Alejandra Tomas; Ben Jones
Journal:  ACS Pharmacol Transl Sci       Date:  2020-03-17

9.  EGFR activity addiction facilitates anti-ERBB based combination treatment of squamous bladder cancer.

Authors:  Michael Rose; Angela Maurer; Julia Wirtz; Andreas Bleilevens; Tanja Waldmann; Maximilian Wenz; Marie Eyll; Mirja Geelvink; Melanie Gereitzig; Nadine Rüchel; Bernd Denecke; Elke Eltze; Edwin Herrmann; Marieta Toma; David Horst; Tobias Grimm; Stefan Denzinger; Thorsten Ecke; Thomas Alexander Vögeli; Ruth Knuechel; Jochen Maurer; Nadine T Gaisa
Journal:  Oncogene       Date:  2020-09-25       Impact factor: 9.867

10.  A physicochemical model of odor sampling.

Authors:  Mitchell E Gronowitz; Adam Liu; Qiang Qiu; C Ron Yu; Thomas A Cleland
Journal:  PLoS Comput Biol       Date:  2021-06-11       Impact factor: 4.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.